Robert Dee Etherington
Chief Executive Officer at CLENE INC.
Net worth: 31 028 $ as of 2024-05-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Reed Wilcox | M | 76 |
Clene Nanomedicine, Inc.
 Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 11 years |
| Shalom Jacobovitz | M | 63 |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 11 years |
| David Matlin | M | 62 |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 4 years |
| Mark Mortenson | M | 65 |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 11 years |
| Vallerie Mclaughlin | M | 60 |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 3 years |
| Alison Mosca | F | 51 |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 5 years |
| Chidozie Ugwumba | M | 41 |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 4 years |
| Jonathon Gay | M | 47 |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 4 years |
| Morgan Brown | M | 55 |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 2 years |
| Chistopher Gibson | M | 41 |
BioUtah
| 5 years |
| Arjun Desai | M | 42 | 1 years | |
| Jerome T. Miraglia | M | 65 | - | |
| Kelvyn H. Cullimore | M | 68 |
BioUtah
| 6 years |
| Robert C. Gay | M | 72 |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 6 years |
| Matthew Kiernan | M | 57 | 1 years | |
| Chad Young | M | - |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | - |
| David Lisonbee | M | - |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | - |
| James D. Stice | M | 64 |
Brigham Young University
| 36 years |
| Michael Hotchkin | M | 50 | - | |
| Mary Anne Moore McNeil | F | - | - | |
| Austin Rynders | M | - | - | |
| Benjamin Greenberg | M | - | 1 years | |
| Adam Dorfman | M | - | 11 years | |
| D. Pierce | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ritch N. Wood | M | 58 |
Brigham Young University
| 5 years |
| Rhonda Powell | F | - |
Brigham Young University
| 5 years |
| Ron F. Gibbs | M | - |
Brigham Young University
| 7 years |
| Jace Jergensen | M | 60 |
Brigham Young University
| 6 years |
| Robert J. Cardon | M | 60 |
Brigham Young University
| 7 years |
| Corey Smith | M | - |
Brigham Young University
| 6 years |
| John Stevens | M | 63 | 10 years | |
| R. Kevin Sellers | M | - |
Brigham Young University
| 6 years |
| Derek Hatch | M | - |
Brigham Young University
| 7 years |
| Mark Oligschlaeger | M | - |
Brigham Young University
| 16 years |
| David A. Jeppson | M | - |
Brigham Young University
| 6 years |
| Scott Gunter | M | - |
Brigham Young University
| 6 years |
| Dayton Judd | M | 52 |
Brigham Young University
| 5 years |
| Michael J. Blaylock | M | - |
Brigham Young University
| 6 years |
| Travis Oliphant | M | - |
Brigham Young University
| 4 years |
| Keith Andrews | M | - |
Brigham Young University
| 5 years |
| David Elliott Faulk | M | - |
Brigham Young University
| 5 years |
| Scott Clair | M | - |
Brigham Young University
| 7 years |
| Jon Tenney | M | - |
Brigham Young University
| 7 years |
| Blake Measom | M | - |
Brigham Young University
| 5 years |
| Erik Lewis | M | - |
Brigham Young University
| 8 years |
| Travis Greenwood | M | - |
Brigham Young University
| 4 years |
| Fiona E. Costello | M | 54 | - | |
| Jeffrey Jensen | M | - |
Brigham Young University
| 8 years |
| Carine Clark | F | 60 |
Brigham Young University
| 2 years |
| Michael Smith | M | 57 |
Brigham Young University
| 5 years |
| Robert Grant | M | 55 |
Brigham Young University
| 6 years |
| Richard T. Callister | M | - |
Brigham Young University
| 7 years |
| James Carpenter | M | - |
Brigham Young University
| 4 years |
| Matt Stephani | M | - |
Brigham Young University
| 5 years |
| Calvin W. Collins | M | 65 |
Brigham Young University
| 7 years |
| Todd P. Clyde | M | 55 |
Brigham Young University
| 5 years |
| Henry Eyring | M | 60 |
Brigham Young University
| 3 years |
| David Bitter | M | - |
Brigham Young University
| 6 years |
| Yu Leung Lau | M | - |
Brigham Young University
| 4 years |
| Timothy Adair | M | 59 |
Brigham Young University
| 6 years |
| D. Bullock | M | 68 |
Brigham Young University
| 10 years |
| Gregory R. Halliday | M | 59 |
Brigham Young University
| 6 years |
| Bradley P. Halverson | M | - |
Brigham Young University
| 4 years |
| David Wayne Lysenko | M | - |
Brigham Young University
| 7 years |
| Reed J. Nuttall | M | - |
Brigham Young University
| 4 years |
| Russell Judd | M | - |
Brigham Young University
| 4 years |
| Brent Whisenant | M | - |
Brigham Young University
| 6 years |
| Doug Haymore | M | - |
Brigham Young University
| 3 years |
| Donald Clouse | M | - |
Brigham Young University
| 6 years |
| Kevin Lund | M | - |
Brigham Young University
| 4 years |
| Sean T. Ristine | M | 54 |
Brigham Young University
| 2 years |
| Martin A. Downen | M | - |
Brigham Young University
| 6 years |
| Joseph Nemelka | M | - |
Brigham Young University
| 4 years |
| Scott Martin Peterson | M | - |
Brigham Young University
| 4 years |
| Stephen Quesenberry | M | 61 |
Brigham Young University
| 4 years |
| Larry Willes | M | - |
Brigham Young University
| 4 years |
| Steven G. Black | M | - |
Brigham Young University
| 4 years |
| Brian Murphy | M | - |
Brigham Young University
| 6 years |
| Christopher Aaron Wilson | M | - |
Brigham Young University
| 3 years |
| David R. Koch | M | 49 |
Brigham Young University
| 4 years |
| Jeffrey David McGhie | M | 54 |
Brigham Young University
| 4 years |
| Todd Nielsen | M | 54 |
Brigham Young University
| 4 years |
| Richard D. Holley | M | - |
Brigham Young University
| 4 years |
| John P. Livingstone | M | 73 |
Brigham Young University
| 3 years |
| Peter Edwards | M | 62 |
Brigham Young University
| 4 years |
| Cristian C. Turrini | M | 49 |
Brigham Young University
| 4 years |
| Steven T. Adams | M | - |
Brigham Young University
| 4 years |
| Kevin Brent Sears | M | - |
Brigham Young University
| 4 years |
| LeGrand Lewis | M | - |
Brigham Young University
| 8 years |
| Todd D. Wilson | M | - |
Brigham Young University
| 4 years |
| Sydne T. Jacques | F | - |
Brigham Young University
| 4 years |
| Gary H. Stewart | M | - |
Brigham Young University
| 4 years |
| Lori Laney | F | - |
Brigham Young University
| 4 years |
| Bryan Hunsaker | M | - |
Brigham Young University
| 4 years |
| Brian Jones | M | - |
Brigham Young University
| 6 years |
| William Whitsel Bryant | M | - |
Brigham Young University
| 4 years |
| Scott Petty | M | 61 |
Brigham Young University
| 6 years |
| B. Shayne Kennedy | M | - |
Brigham Young University
| 4 years |
| Joel Arbuckle | M | - |
Brigham Young University
| 6 years |
| Micheal J. Reagan | M | - |
Brigham Young University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
| Switzerland | 0 | -.--% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Robert Dee Etherington
- Personal Network
